PMID: 8443400Jan 1, 1993Paper

Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate

Breast Cancer Research and Treatment
S LiF Labrie

Abstract

Since our previous findings had indicated that the androgenic steroid medroxyprogesterone acetate (MPA) exerts potent inhibitory effects on 7,12-dimethylbenz(a)anthracene (DMBA)-induced tumor growth, we have studied the effect of low doses of MPA released from Depo-Provera and from 50:50 poly[DL-lactide-co-glycolide] microspheres in the same DMBA-induced tumor model. The present data show that single subcutaneous injection of a 4-month controlled-release formulation of biodegradable 50:50 poly[DL-lactide-co-glycolide] microspheres containing 10 mg of MPA giving serum levels of 3.14 +/- 0.32 ng/ml (8.12 +/- 0.83 nM) MPA causes a maximal or near-maximal 60% inhibition of tumor growth measured 56 days later. Such data suggest that controlled-release formulations giving constant and low blood levels of MPA could be used for the treatment of breast cancer in women. Such a low concentration of MPA should avoid the side effects observed with the high doses of the compound.

References

May 1, 1975·Journal of Steroid Biochemistry·H MaassG Trams
Jan 1, 1976·Current Topics in Molecular Endocrinology·L FerlandF Labrie
Jan 22, 1990·Molecular and Cellular Endocrinology·C LabrieF Labrie
Jan 1, 1990·Annals of the New York Academy of Sciences·A BélangerA Angeli
Dec 1, 1989·Breast Cancer Research and Treatment·S DauvoisF Labrie
Jan 1, 1985·Cancer Chemotherapy and Pharmacology·H van VeelenH Doorenbos
Jan 1, 1985·Breast Cancer Research and Treatment·G N HortobagyiG R Blumenschein
Jan 1, 1987·Journal of Steroid Biochemistry·K B Horwitz
Apr 1, 1985·European Journal of Cancer & Clinical Oncology·W R MillerR A Hawkins
Aug 1, 1974·British Journal of Cancer·E EngelsmanF J Cleton
Oct 1, 1970·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J C HeusonN Legros
Jan 1, 1983·Breast Cancer Research and Treatment·W Mattsson
Feb 1, 1980·Journal of Steroid Biochemistry·A BélangerV Picard
Jun 1, 1964·Proceedings of the Society for Experimental Biology and Medicine·P K TALWALKERH MIZUNO
Aug 13, 1949·Journal of the American Medical Association·F E ADAIR, R C MELLORS

❮ Previous
Next ❯

Citations

Jul 7, 1997·Advanced Drug Delivery Reviews·W M Saltzman, L K Fung
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R NishimuraK Ikeda
Feb 4, 2011·International Journal of Nanomedicine·Shang SongThomas J Webster
Jul 27, 2012·Hormones & Cancer·Michael R Moore, Rebecca A King
Dec 22, 2011·Journal of the American Animal Hospital Association·Luis LoboClaudio Bussadori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.